Drug pusher

Roche thinks a healthy dose of cash will make it easier for Genentech minorities to swallow the idea of selling out to their biggest shareholder. The Swiss drugs group announced its intention to bypass directors of US-based Genentech, in which it already owns a 56% stake, and go right to other investors with a $42bn cash bid. It’s a 3% cut to the original offer presented last July – which was rejected a month later. Independent Genentech directors were still engaged in talks with Roche, but acco...